Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 are standard treatments for advanced cancers like melanoma and NSCLC.
• Dermatologic adverse events are the most frequent side effects of these immunotherapies.
• Bullous pemphigoid (BP) is an autoimmune blistering disease that can be triggered by various medications.

Observation:

• A patient undergoing combination therapy with durvalumab (anti-PD-1) and tremelimumab (anti-CTLA-4) developed bullous pemphigoid.
• Durvalumab and tremelimumab are novel immunotherapy checkpoint inhibitors currently under investigation in phase III clinical trials.

Findings:

• The development of bullous pemphigoid represents a rare but significant dermatologic toxicity associated with the combination of durvalumab and tremelimumab.
• This case underscores the potential for immune-related adverse events beyond common skin toxicities with novel ICI combinations.

Implications:

• Clinicians should maintain a high index of suspicion for autoimmune blistering diseases like BP in patients treated with novel ICI combinations.
• Early recognition and management of BP are crucial to mitigate potential morbidity and allow for continued oncologic treatment if appropriate.
• Further research is warranted to elucidate the mechanisms underlying ICI-induced BP and to develop predictive or preventative strategies.